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Abstract
The 11,12-epoxy-eicosatrienoic acid (11,12-EET) is formed from arachidonic acid (AA) by cytochrome P450 2J2 (CYP 2J2)
epoxygenase and function as an effector in blood vessels. Human endothelial progenitor cells (hEPCs), a preceding cell
source for endothelial cells (ECs), involve in the vascular tissue repairing by postnatal neovasculogenesis. However, the
effect of 11, 12-EET on hEPCs and neovasculogenesis is not well known. In the current study, we examined the function of
11, 12-EET in hEPCs-mediated neovasculogenesis by using tubular formation analysis, Western Blotting assay, immunoﬂuorescence staining, ﬂow cytometry analysis and zymogram analysis. The results suggest that 11, 12-EET signiﬁcantly
induces neovasculogenesis through the phosphorylation of phosphoinositide 3-kinase (PI3eK)/Akt, endothelial-nitric
oxide synthase (e-NOS) and extracellular signal-regulated kinase 1/2 (ERK 1/2) signaling pathways. 11, 12-EET up-regulates the expression of cyclin D1, cyclin edependent kinase 4 (CDK4) and nuclear factor kappa B (NF-kB) proteins.
Moreover, 11, 12-EET augments the expression of VE-cadherin and CD31 proteins in hEPCs. 11, 12-EET also augmented
Rac1/Rho A signaling cascades, cell migration and an up-regulation of matrix metalloproteinase (MMP) ¡2 and ¡9
proteins. These results demonstrate that 11, 12-EET exerts a signiﬁcant function in the neovasculogenesis of hEPCs.
Keywords: 11,12-Epoxyeicosatrienoic acid, Neovasculogenesis, eNOS, Human endothelial progenitor cells

1. Introduction

B

one marrow (BM) provides stem cells and
endothelial progenitor cells (hEPCs) for tissue
repairment and the prevention of ischemic injuries
[1]. Study indicated that human BM-derived
hemangioblast, a preceding progenitor for

hematopoietic cells, are evolved consequently into
hEPCs/endothelial colony forming cells (ECFCs)
and endothelial cells (ECs) during embryogenesis
and provides the sources for neovascularization [2].
Many studies also suggest that hEPCs are implicated in postnatal neovasculogenesis/angiogenesis
process in the adulthood [3,4]. Signaling cascades

Received 27 December 2021; revised 6 January 2022; accepted 11 January 2022.
Available online 01 September 2022
* Corresponding author. Fax: þ886-4 22062891.
E-mail address: vincenttang@mail.cmu.edu.tw (F.-Y. Tang).
1
Present address. Biomedical Science Laboratory, Department of Nutrition, China Medical University, No. 100, Sec.1, Jing-Mao Road, Taichung 40604,
Taiwan, Republic of China.
2
Coauthorships: These authors equally contributed to this work.
https://doi.org/10.37796/2211-8039.1343
2211-8039/Published by China Medical University 2022. © the Author(s). This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

lead to the neovascularization are involved in the
proliferation and outgrowth of hEPCs [5]. Recent
studies suggested several important roles of BM
-derived circulating hEPCs in neovascularization
during different conditions such as wound healing
and ischemic injuries [6e8]. Previous studies suggested that the phosphorylation of Akt and extracellular signal-regulated kinase 1/2 (ERK 1/2)
proteins induces the proliferation of hEPCs through
an increment of nuclear factor kappa B (NF-kB),
cyclin D1 and cyclin edependent kinase 4 (CDK4)
proteins [9,10]. The activation of Akt further augments the phosphorylation of downstream targets
nuclear factor kappa B inhibitor (IkBa) and endothelial-nitric oxide synthase (e-NOS) proteins to
enhance cell migration capability [11]. Moreover,
small GTPases such as Rho A and Rac1 proteins are
involved in cell movement and angiogenesis
through the changes of cytoskeleton, assembly of
contractile stress ﬁbers and ﬁlopodial/lamellipodial
extension [12]. These evidences suggest that RhoA
and Rac1 proteins play important roles in cell
migration through a modulation of actin cytoskeleton and the stability of microtubules [13,14]. A
study also indicated that matrix metalloproteinase
(MMP) proteins are involved in the cell recruitment and migration of hEPCs during the neovascularization process [15]. MMP-9 is involved in
the augmentation of cell motility of BM-derived
progenitor cells [15,16]. Recent study suggests that
ECFCs, a late stage of hEPC population, possess the
characteristics of a true endothelial progenitor and
has a potential to differentiate into ECFCs [17]. A
signiﬁcant up-regulation of CD31 and VE-cadherin
was observed during the differentiation of hEPCs
into mature ECs [18e20].
A study indicate that CYP2J2 epoxygenase is
expressed in vascular ECs and responsible for the
conversion of arachidonic acid to the eicosanoid
metabolites including 11,12- epoxyeicosatrienoic
acids (EETs) [21]. An earlier study suggested that
EETs involved in the VEGF-mediated angiogenesis
and cancer development [22]. Therefore, the current
study would examine the molecular mechanisms of
11, 12-EET in hEPCs-mediated neovasculogenesis.

2. Methods
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Akt (p-Akt S473; #4060), total-Akt (t-Akt; #2964),
phosphorylated eNOS (p-eNOS S1177; #9571), totaleNOS (t-eNOS; #5880S), phosphorylated ERK 1/2
(p-ERK 1/2 T202/Y204; #9101), total- ERK 1/2 (t- ERK 1/
2; #9102), phosphorylated IkBa (p- IkBa S32/36;
#9246S), VE-cadherin (#2500S), RhoA (#2117P),
phosphorylated Rac1 (p-Rac1 S71; #2461), anti-CDK4
(#2906) and phosphorylated p65 (p-p65/RelA;
#3033T). Lamin A (sc-7292), cyclin D1 (sc-8396) and
actin (sc-1616) antibodies were purchased from
Santa Cruz Biotechnology, Inc (Dallas, TX, USA).
MCDB-131 medium, MTT, 11,12-EET (purity >99%),
12-(3-adamantan-1-yl-ureido)
dodecanoic
acid
(AUDA) (soluble epoxide hydrolase inhibitor),
PD098059 (MEK inhibitor), Bay-11-7082 (NF-kB inhibitor), wortmannin (PI3eK inhibitor) and LNAME (eNOS inhibitor) were acquired from Sigma
(St Louis, MO). A commercial protein extraction kit,
NE-PER, was purchased from Pierce Biotechnology
(Lackford, IL). Fetal bovine serum (FBS) was obtained from the Thermo Fisher Scientiﬁc (Pittsburgh, PA). EGM-2 growth kit was purchased from
Lonza, Inc. (Allendale, NJ). hEPC was a kind gift and
provided by Dr. S.C. Chiu (China Medical University, Taichung, Taiwan).
2.2. Cell culture procedure
hEPCs were seeded onto culture dish and
cultured in MCDB-131 medium with EGM-2 growth
kit and 10% fetal bovine serum (FBS). Culture media
were changed every 2 days. For these in vitro experiments, 11,12-EET was dissolved in dimethyl
sulfoxide (DMSO) at a stock solution of 100 mM.
hEPCs were treated with 11,12-EET (for 8 h) for
further analysis of neovascularization, protein
expression, cell migration, proliferation or zymogram analysis.
2.3. Assessment of cell survival
hEPCs (2  104 cells) were seeded in 24- well
plates with MCDB-131 medium containing 11,12EET and different inhibitors for 8h. MTT assay was
used to measure the cell proliferation. At the end of
the experiment, the optical absorbance was analysed at wave length of 570 nm with a microplate
reader.

2.1. Reagents and antibodies
2.4. Extraction of cellular proteins
The matrigel and monoclonal antibody against
CD31 (BD 550274) protein were obtained from BD
Bioscience (San Jose, CA). The following antibodies
were purchased from the CST (Cell Signaling
Technology) (Danvers, MA, USA): phosphorylated

Protein extractions were executed by NE-PER kit
with inhibitors of phosphatase and protease. To
remove the cell debris, cellular proteins were
centrifuged for 10 min at 12,000g. The remaining

ORIGINAL ARTICLE

BioMedicine
2022;12(3):20e30

22

H.-C. HUNG ET AL
NEOVASCULOGENIC EFFECTS OF 11,12-EET

ORIGINAL ARTICLE

supernatants were obtained as a cytoplasmic
fraction.
2.5. Western Blotting analysis
Cellular proteins (70 mg) were separated by
running in 10% sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The
resulting SAS-PAGE gel was electroblotted to polyvinylidene diﬂuoride (PVDF) membrane and
covered with primary antibody solution. The blots
were stripped and reprobed with internal control
antibody.
Detection of other proteins including p-ERK 1/2,
p-Akt, p-eNOS, p- IkBa, p-Rac 1 and RhoA was
performed by using similar procedure described
above. The t-ERK 1/2, t-Akt and t-eNOS antibodies
were used as internal controls for p-ERK 1/2, p-Akt,
p-eNOS proteins, respectively. Expression of nuclear proteins including cyclin D1, p65/NF-kB (RelA)
and CDK4 was measured by also using similar
procedure. The Lamin A protein was used as internal control.
2.6. Vascular tube formation assay
For the vascular tube formation assay, aliquots of
50 mL matrigel (4 mg/mL) were transferred to each
well of a 96-well plate and incubated at 37  C until
gelatinization occurred. For the neovasculogenesis
assay, hEPCs (1  104 cells) were cultured in the
matrigel-coated 96 well plate with 10% FBS MCDB131 medium. After cell seeding for 8 h, photos of
neovasculogenesis was documented under inverted
phase-contrast microscope. The ﬁnal results were
collected for data analysis by using the accessory
software (Olympus imaging system) (Tokyo, Japan).
2.7. F-actin assembly detection
hEPCs growing on culture Tek-chamber slides
with 11,12- EET (0 and 50 nM) at different time
points (0, 0.5 and 2 h) were ﬁxed with phosphate
buffer saline (PBS) containing 3.7% formaldehyde
and labeled with 5 units/mL of Alexa 488 phalloidin
(Invitrogen Inc.). Cells were rinsed three times with
PBS and were monitored using Confocal Microscope Detection System (Leica, Wetzlar, Germany)
to perform image documentation and analysis.

BioMedicine
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anti-human VE-cadherin-PE solution. Cells stayed
on ice for 30 min until analysis by BD FACS Canto
ﬂow cytometry (BD Biosciences, Franklin Lakes, NJ).
Results from staining cells were analyzed using the
accessory software.
2.9. Gelatin zymography
Supernatant protein (20 mg) from conditioned
medium of cultured hEPCs was transferred into an
8% polyacrylamide gel containing gelatin. At the
end of electrophoresis, the polyacrylamide gel was
washed with 2.5% Triton X-100 at room temperature
and subsequently incubated in a reaction buffer
(10 mM CaCl2, 0.15 M NaCl and 50 mM Tris) at
37  C overnight. To detect the enzymatic reaction of
MMPs, gel was covered with 0.25% Coomassie blue
solution and photograph documented on a light
box. Proteolysis within polyacrylamide gel was
observed as a white range in a dark ﬁeld.
2.10. Statistical analysis
The biostatistic analysis was performed to investigate the difference in the vascular formation between
11,12-EET groups and control group of hEPCs by
using SYSTAT software (Chicago, IL, USA). Conﬁrmation of difference in neovasculogenic index was
performed by using the one way ANOVA model and
Tukey's post hoc test at the P ¼ 0.05 level. Conﬁrmation of difference in protein expression was performed by using student t-test at the P ¼ 0.05 level.

3. Results
3.1. 11,12-EET signiﬁcantly induced
neovasculogenesis of hEPCs in vitro
In this study, we investigated the effects of 11,12EET on neovasculogenesis in hEPCs. 11,12-EET (at
concentrations of 3, 30 and 50 nM) induced neovascularization of hEPCs by around 1.36, 1.5 and 1.61
folds (P < 0.05), respectively (Fig. 1). Treatment of
AUDA (at a concentration of 10 nM), an speciﬁc inhibitor for soluble epoxide hydrolase (sEH), further
enhanced 11,12-EET -mediated neovasculogenesis in
hEPCs (P < 0.05). These ﬁndings indicate that 11,12EET is involved in the neovasculogenesis of hEPCs.

2.8. Flow cytometric analysis of biomarker proteins

3.2. Akt, eNOS, NF-kB and MAPK/ERK signaling
cascades involve in 11,12-eet-mediated
neovasculogenesis

hEPCs for biomarker analysis were stained with
either anti-human c-kit-ﬂuorescein isothiocyanate
(FITC), anti-human CD31-phycoerythrin (PE) or

In the current study, we further examined
possible signaling pathways in 11,12-EET -mediated

EET (nM)
AUDA (nM)

0
0

3
0

30
0

50
0

50
10

Fig. 1. 11,12-EET signiﬁcantly induced neovasculogenesis of hEPCs in
vitro. hEPCs were cultured with 11,12-EET (0, 3, 30 and 50 nM) with or
without AUDA (a speciﬁc inhibitor of sEH) for 8 h until the measurement of neovascularization. These values are presented as
mean ± standard deviation (SD) in randomly selected ﬁelds in each
well. Experiment was performed and reconducted three times. A single
asterisk (*) indicates a statistic difference compared to the 11,12EET-untreated group (P < 0.05). A pound sign (#) indicates a statistic
difference compared to the 11,12-EET (50 nM)- treated subgroup
(P < 0.05).

neovasculogenesis. Treatment with wortmannin (a
speciﬁc inhibitor of PI3eK), PD098059 (a speciﬁc inhibitor of MEK), Bay- 11e7082 (a speciﬁc inhibitor of
NF-kB) or L-NAME (a speciﬁc inhibitor of eNOS)
suppressed 11,12-EET -mediated formation of tubular
structures in hEPCs, respectively (P < 0.05) (Fig. 2 A &
B). At a dosage of 10 mM, wortmannin and PD098059
signiﬁcantly inhibited 11,12-EET -mediated neovascularization up to 75% and 57% respectively. Bay11-7082 (1 mM) and L-NAME (0.1 mM) each inhibited
11,12-EET -mediated neovascularization up to 60%
and 47%. The results also suggested that wortmannin,
PD098059, Bay-11-7082 and L-NAME had no cytotoxicity against hEPCs (Fig. 2C). Results suggest that
wortmannin, PD098059, Bay-11-7082 and L-NAME
exert inhibitory effects on neovasculogenesis without
exerting any cytotoxicity. These results indicate that
the Akt, eNOS, NF-kB and ERK1/2 molecules are
involved in 11,12-EET - mediated neovasculogenesis.
3.3. 11,12-EET induced neovasculogenesis through
increment of phosphorylated Akt, eNOS and ERK
1/2 proteins in hEPCs
We further examined whether 11,12-EET would
alter the expression of VE-cadherin biomarker
protein and the activation of these signaling cascades in hEPCs. 11,12-EET signiﬁcantly increased
the expression of VE-cadherin protein in hEPCs
(P < 0.05) (Fig. 3A). Moreover, 11,12-EET signiﬁcantly induced the phosphorylation levels of ERK 1/
2, Akt, eNOS and IkBa proteins in hEPCs.
It seems probable, therefore, that 11,12-EET
effectively functioned as neovasculogenic agents
through increased expression of VE-cadherin
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proteins as well as the phosphorylation levels of
PI3eK/Akt, eNOS, NF-kB, and MAPK/ERK
signaling molecules.
To further examine the neovasculogenic effects of
11,12-EET in hEPCs, we measured the expression of
nuclear proteins. As shown in Fig. 3B and 11,12-EET
enhanced nuclear level of NF-kB (p-p65; RelA)
protein in hEPCs. Moreover, 11,12-EET signiﬁcantly
augmented the expression of cyclin D1 and CDK4
proteins in hEPCs. These results suggested that
11,12-EET mediated neovasculogenesis in hEPCs.
3.4. 11, 12-EET signiﬁcantly induced the expression
of VE-cadherin and CD31 proteins in hEPCs
To further investigate the vasculogenic effects of
11,12-EET in hEPCs, we measured the expression of
VE-cadherin, CD31 and c-kit biomarker proteins by
using ﬂow cytometry analysis. In Fig. 4, treatment of
11,12-EET signiﬁcantly increased the VE-cadherinþ
and CD-31þ cell subpopulations of hEPCs. These results suggested that EET treatment might augment the
differentiation of hEPCs toward to VE-cadherinþ/
CD31þ late EPCs (ECFCs).
3.5. 11,12-EET augmented Rac1/Rho A cascade,
cell migration and upregulation of MMP-2,-9
proteins in hEPCs
To verify actions of 11, 12-EET on cell migration,
we further elucidated the probable effects of 11,12EET on Rac 1 and Rho A proteins. As demonstrated
in Fig. 5A and 11,12-EET increased phosphorylated
levels (i.e. activation) of the RAC 1 and an upregulation of Rho A proteins. The results suggested
that 11,12-EET could modulate cell migration and
enhance the expression of phosphorylated-Rac 1
and Rho A proteins in hEPCs.
To conﬁrm these ﬁndings, we further examined
whether 11,12-EET altered the distribution of F-actin
proteins in hEPCs. As shown in Fig. 5B, F-actin
stress ﬁbers is randomly distributed in hEPCs at
starting time point (Fig. 5B, a-b). Treatment of 11,
12-EET (50 nM) signiﬁcantly induced the redistribution of F-actin stress ﬁbers into a well-aligned
pattern in hEPCs (Fig. 5B, c-f). 11,12-EET also
signiﬁcantly induces cell migration of hEPCs
(P < 0.05) (Fig. 5C). Our results demonstrated that
11,12-EET increased cell proliferation levels in
hEPCs (Fig. 5D). Previous study suggested that
neovasculogenesis and angiogenesis are correlated
with an increasing enzymatic activity of MMP-2 and
MMP-9 proteins. Therefore, we further investigated
whether 11,12-EET modulated MMP-2 and MMP -9
expression in hEPCs. In Fig. 5E, 11,12-EET
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(A)
Control

EET (50 nM)

EET (50 nM) +Wortamannin 10 M

EET (50 nM) +PD098059 10 M

EET (50 nM) +Bay-11-7082 1 M

EET (50 nM) +L-NAME 0.1 mM

(B)

(C)

Fig. 2. Akt, eNOS, NF-kB and MAPK/ERK signaling cascades involve in 11,12-EET-mediated neovasculogenesis. hEPCs were treated with wortmannin (10 mM), PD098059 (10 mM), Bay-11-7082 (1 mM) and L-NAME (0.1 mM) in the presence of 11,12-EET (50 nM) for 8 h until the analysis of
neovasculogenesis (A). The values represent mean ± SD for the quantitative results (B). A single asterisk (*) indicates a statistical difference in
comparison with the 11,12-EET-treated group (P < 0.05). Double asterisks (**) indicate a statistical difference in comparison with the 11,12-EETuntreated control group (P < 0.05). Viability analysis of hEPCs was performed under the same treatments. The proliferation index is provided as
mean ± SD (C). Different letters represent signiﬁcant differences of proliferation index among subgroups.

effectively augmented the enzymatic activities of
both MMP-2 and MMP-9 (P < 0.05). The results
suggested that 11,12-EET exerted neovasculogenesis

activity and induced the breakdown of extracellular
matrix through an upregulation of MMP-2 and
MMP-9 proteins in hEPCs.
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Fig. 3. 11,12-EET induced neovasculogenesis through increment of phosphorylated Akt, eNOS and ERK 1/2 proteins in hEPCs. hEPCs were treated
with 11,12-EET (at concentrations of 0, 3, 30 and 50 nM) for 8 h. (A) Measurement of cytoplasmic proteins including VE-cadherin, p-Akt, t-Akt, peNOS, t-eNOS, p- IkBa, p- ERK1/2, t-ERK 1/2 and actin was performed by using Western Blotting analysis as described in Materials and Methods.
The integrated densities (mean ± SD) of each protein (VE-cadherin, p- IkBa, p-Akt, p-eNOS, p- ERK1/2) are adjusted with the corresponding control
proteins (actin, t-Akt, t-eNOS or t-ERK 1/2) and shown in the bottom row. A single asterisk indicates a statistical difference in comparison with the
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Fig. 4. 11, 12-EET signiﬁcantly induced the expression of VE-cadherin and CD31 proteins in hEPCs. The hEPCs were incubated cultured with 11, 12EET (at concentrations of 0, 3, 30 and 50 nM) in 10% FBS MCDB-131 for 8 h. Detection of VE-cadherin, CD31 and c-kit proteins hEPCs were stained
with speciﬁc monoclonal antibodies and measured by using ﬂow cytometry analysis as described in Materials and Methods. The amount of detection
(mean ± SD) represented the expression level of VE-cadherin and CD31 and c-kit proteins on the surface of h EPCs. Single asterisk represented a
statistical difference in comparison with 11,12- EET-untreated control group (P < 0.05).

4. Discussion
Many studies already showed that neovasculogenesis and angiogenesis play key steps in the

physiological and pathological conditions including
ischemia prevention and tumor development [23].
Moreover, studies suggested important roles of
EETs in cardioprotection, angiogenesis and tumor

11,12-EET untreated control group (P < 0.05). (B) Analysis of nuclear proteins were conducted using antibodies against cyclin D1, CDK4, p-p65
(RelA) and lamin A. The integrated densities (mean ± SD) of these proteins are adjusted with the loading control lamin A protein are shown in the
bottom row. A single asterisk represented a statistical difference in comparison with 11,12 -EET-untreated control group (P < 0.05).
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(C)
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(0.17)

1.90＊
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(D)
Control

d

f

b

EET
(50 nM)

(E)

EET (nM)

0
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MMP-2
1.00
(0.02)

1.42＊
(0.03)

1.46＊
(0.04)
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(0.01)
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(0.05)

1.88＊
(0.08)

1.65＊
(0.17)

MMP-9

Fig. 5. 11,12-EET augmented Rac1/Rho A cascade, cell migration and upregulation of MMP-2,-9 proteins in hEPCs. (A) hEPCs were treated with
11,12-EET (0, 3, 30 and 50 nM) in 10% FBS MCDB-131 for 8 h. Measurement of cytoplasmic proteins including p-Rac1, RhoA and actin was
performed by using Western Blotting analysis. The integrated densities (mean ± SD) of p-Rac1and RhoA proteins adjusted with the corresponding
loading control protein (actin) are shown in the bottom row. A single asterisk indicates a statistical difference in comparison with the 11,12-EET
-untreated control group (P < 0.05). (B) hEPCs were treated in the presence or absence of 11,12-EET (at a concentration of 50 nM) in 10% FBS
MCDB-131 at different time points (0, 0.5 and 2 h). F-actin stress ﬁber were stained with anti-F-actin-FITC antibody using immunoﬂuorescence
staining. Imaging was documented at 400 magniﬁcation. Green ﬂuorescence indicates the distribution of F-actin. The alignment of F-actin stress
ﬁbers was indicated with a yellow arrow. The blue spot represents the distribution of cell nuclei. hEPCs were cultured with 11,12-EET (at concentrations of 3, 30 and 50 nM) for 8 h until the measurement of cell migration (C) and cell proliferation (D). The values are the mean ± SD in 8
randomly selected ﬁelds in each culture well, each carried out in triplicate and repeated twice. A single asterisk (*) indicates a statistically signiﬁcant
difference compared to the 11,12-EET-untreated control group (P < 0.05). (E) hEPCs were treated with 11,12-EET (0, 3, 30 and 50 nM) in MCDB-131
for 8 h. Conditioned media were collected for zymogram analysis. The levels of detection represented the expression of MMP-2 and MMP-9 proteins
secreted from hEPCs. The densities (mean ± SD) of these proteins are shown in the bottom row. A single asterisk represents a signiﬁcant difference of
MMP-2 or MMP-9 expression in comparison to the 11,12-EET- untreated group (P < 0.05).

metastasis [22,24,25]. Therefore, EETs seem to play
important roles in many aspects of chronic diseases.
Adult neovasculogenesis occur through the circulating hEPCs into vascular sites and the proliferation
of ECs [26e28]. A recent study suggested that welldifferentiated ECs with a low proliferative potential
have low repairing capability for damaged ECs.
hEPCs from adult BM obtain an early-onset differentiated capacity, an excellent repairing capability
and neovasculogenesis-prone characteristics.
Many studies suggested that EETs generated by
cytochrome P450 epoxygenases are vasodilators eicosanoids [29,30]. These P450 epoxygenases CYP2J2

are highly expressed in vascular ECs and capable of
metabolizing arachidonic acid into several types of
EETs including 11,12-EET [21]. Previous studies
showed that a risk of CAD is inversely correlated
with the levels of the Cytochrome P450 epoxygenases CYP2J2 and 11,12 EET [31,32]. EETs are
also involved in the VEGF-mediated angiogenesis
processes [22]. These results suggested that 11,12EET has favorable effects on increasing endothelial
functions, neovasculogenesis and even angiogenesis. A recent study indicated that 11,12-EET could
promote organ and tissue regeneration [33]. Moreover, 11,12-EET could rescue impaired wound
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healing under ischemic condition [34]. These in vivo
ﬁndings suggested that 11,12-EET could act as an
effective agent to increase neovascularization and
prevent ischemic injuries.
For the ﬁrst time, we demonstrated that 11,12-EET
induces neovascularization/angiogenesis through
an EPC- differentiation into EC- like characteristics.
The results showed that 11,12-EET signiﬁcantly
augmented neovasculogenesis of hEPCs, in part,
through an up-regulation of VE-cadherin protein in
vitro. The molecular actions of 11,12-EET were mediated through the activation of signaling pathways
including Akt, eNOS and ERK 1/2 signaling cascades.
11,12-EET also augmented the expression of RhoA and
the phosphorylation of Rac 1 proteins. These novel
ﬁndings suggested that 11,12-EET may function as a
signaling effecter to induce neovasculogenesis.
The results further demonstrated that 11,12-EET
signiﬁcantly increased the nuclear levels of cyclin D1
and CDK4 proteins in hEPCs. There are several
possible scenarios for 11,12-EET to induce neovasculogenesis and angiogenesis. One explanation
might be predominant activation of Akt, eNOS and
MAPK/ERK molecules in hEPCs. Neovascularization
requires the activation of Akt and ERK 1/2 pathways
and eNOS protein in hEPCs. The Akt-mediated
phosphorylation of eNOS would lead to an increasing
cell migration of endothelial cells [35]. Inhibition of the
signaling cascades including PI3eK/Akt and eNOS
pathways was also correlated with increased apoptosis
level in ECs [35]. Our results suggested that 11,12-EET
plays an important role by induction of NO bioavailability in vascular tissues. Although we have not
examined the stability of 11,12-EET and the metabolic
consequence, it is probable that 11,12-EET obtains its
effect on neovascularization.
Alternatively, we identify a new role of 11,12-EET
in the upregulation of cyclin D1 and CDK4 proteins
in hEPCs. It is probable that a closely correlation
between the expression of cyclin D1 and CDK4
proteins in 11, 12-EET mediated neovasculogenesis.
Results from the current study further implicated
that 11,12-EET probably induced the differentiation
of hEPCs into ECFCs (late-EPCs) through increased
levels of VE-cadherin and CD31 proteins. Based on
our observation, it is probable that 11,12-EET may
function as an agent to induce differentiation of EPC
into ECFCs. After all, 11,12-EET induced the differentiation of EPC into ECFCs and the proliferation
of these cells through augmented expression of
cyclinD1 and CDK4 proteins as well as the neovasculogenesis in hEPCs. These results prove the
neovasculogenic and angiogenic effects of 11,12EET. It may explain the important roles of 11,12-EET
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Fig. 6. Proposed mechanisms of 11, 12-EET-mediated neovasculogenesis
in hEPCs. Green arrow indicates an increased level.

in the differentiation of BM-derived hEPCs and the
proliferation of ECFCs.
To validate these important ﬁndings, we also
measured the expression of MMP-2 and MMP-9
proteins in these 11,12 EET-treated EPCs. As shown
in Fig. 5, these results suggested that 11,12-EETmediated cell migration and neovascularization
were associated with augmented expression of
MMP-2 and MMP-9 proteins in hEPCs. Augmented
expression of MMP proteins and the activation of
Rac 1 and RhoA molecules are observed in the 11,12
- EET -mediated neovasculogenesis. Although we
have not veriﬁed the crucial role of 11,12-EET in
experimental animal model yet, the probable limitation is to measure the bioavailability of 11,12-EET
in an in vivo study. Previous studies indicated that
increased activities of endothelial progenitor cells
could play important roles in increment of wound
healing, tissue repairment and tissue regeneration
[1]. One of probable utilization of 11,12-EET could
be applied to promote wound healing or tissue
repairment in future clinical application.

5. Conclusion
In conclusion, the speciﬁc novel aspects of this
study include the neovasculogenic effects of 11,12EET on (i) the activation of PI3eK/Akt, eNOS and
ERK 1/2 signaling pathways; (ii) the differentiation
of EPCs into ECFCs; (iii) the proliferation of EPCs;
and (iv) the cell migration of EPCs. The proposed
mechanism was described in Fig. 6. Our results
might provide an important insight leading to the
application of 11,12-EET in the future preclinical
and clinical studies.
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